Effect of Alteplase Combined with Butylphthalein on Thrombolytic Therapy in Patients with Ultra-early Acute Cerebral Infarction
Objective To analyze the clinical effect of thrombolytic therapy of alteplase combined with butylphthalein in patients with ultra-early acute cerebral infarction.Methods The clinical data of 96 patients with ultra-early acute cerebral infarction admitted to Zaozhuang Shizhong District People's Hospital from July 2020 to June 2022 were retro-spectively selected.According to different treatment methods,they were divided into observation group(given al-teplase combined with butylphthalein thrombolytic therapy)and control group(given alteplase intravenous thrombo-lytic therapy),with 48 cases in each group.The effective rate of treatment,the scores of nerve function and activity of life,and the incidence of adverse reactions were compared between the two groups.Results After treatment,the total treatment efficiency and life activity scores of the observation group were higher than those of the control group,and the neurological function scores were lower than those of the control group,the differences were statistically significant(all P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Combined thrombolytic therapy for acute cerebral infarction has good clinical effect and can effec-tively promote the recovery of nerve function and daily activity ability.
Ultra-earlyAcute cerebral infarctionAlteplaseIntravenous thrombolysisButylphthaleinNeural function
NETL
NSTL
万方数据
